Monte Rosa Therapeutics Expects Its Cash And Cash Equivalents Of $197.8M To Be Sufficient To Fund Planned Operations And Capital Expenditures Into The First Half Of 2026
Monte Rosa Therapeutics Expects Its Cash And Cash Equivalents Of $197.8M To Be Sufficient To Fund Planned Operations And Capital Expenditures Into The First Half Of 2026
Monte Rosa Therapeutics預計，其1.978億美元的現金和現金等價物將足以爲2026年上半年的計劃運營和資本支出提供資金
Monte Rosa Therapeutics Expects Its Cash And Cash Equivalents Of $197.8M To Be Sufficient To Fund Planned Operations And Capital Expenditures Into The First Half Of 2026
Monte Rosa Therapeutics預計，其1.978億美元的現金和現金等價物將足以爲2026年上半年的計劃運營和資本支出提供資金
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。